Last reviewed · How we verify

COLD BLOOD BASED CARDIOPLEGIA

JESSICA GARCIA SUAREZ · FDA-approved active Small molecule

Cold blood-based cardioplegia is a solution used during cardiac surgery to induce cardiac arrest and protect the heart from ischemic injury by rapidly cooling and chemically arresting myocardial function.

Cold blood-based cardioplegia is a solution used during cardiac surgery to induce cardiac arrest and protect the heart from ischemic injury by rapidly cooling and chemically arresting myocardial function. Used for Myocardial protection during cardiac surgery requiring cardiopulmonary bypass.

At a glance

Generic nameCOLD BLOOD BASED CARDIOPLEGIA
Also known asCARDIBRAUN
SponsorJESSICA GARCIA SUAREZ
Drug classCardioplegic solution
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

This cardioplegic solution combines cold temperature with electrolyte composition (typically high potassium) to stop the heart's electrical and mechanical activity, reducing myocardial oxygen demand during surgical procedures. The hypothermia provides metabolic protection to cardiac tissue, while the chemical composition maintains electrolyte balance and prevents reperfusion injury when normal circulation is restored.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: